Medical/Pharmaceuticals
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...
2023-11-09 08:10
4111
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...
2023-11-09 08:00
1553
Holmusk Appoints Eze Abosi as Chief Growth Officer
New CGO joins Holmusk during a period of strong and sustainable growth for both
the life science and payer/provider businesses.
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Holmusk
2023-11-09 08:00
1270
Telix to Present at Jefferies London Healthcare Conference 2023
MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...
2023-11-09 04:51
1524
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology
TAIPEI, Nov. 8, 2023 /PRNewswire/ -- * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...
2023-11-08 23:23
1732
Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development
SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...
2023-11-08 22:31
1809
Seoul National University Bundang Hospital (SNUBH) Secures Prestigious GHA Accreditation, Reinforcing Its Position as a Premier Global Medical Travel Destination
PALM BEACH GARDENS, Fla., Nov. 8, 2023 /PRNewswire/ -- Seoul National University Bundang Hospital (SNUBH), one of South Korea's most prestigious healthcare institutions, is delighted to announce that it has achieved a second consecutive term of Accreditation with Excellence fromGlobal Healthcare ...
2023-11-08 19:00
1561
The 2023 Asia Health and Life Sciences Innovation and Cooperation Summit Delivered Insights on the Future of Healthcare
SINGAPORE, Nov. 8, 2023 /PRNewswire/ -- The 2023 Asia Health and Life Sciences Innovation and Cooperation Summit (AHLSICS), hosted by ASK Health Asia and the SingHealth Duke-NUS Global Health Institute (SDGHI), in collaboration with the World Economic Forum, successfully concluded in Singapore on 1s...
2023-11-08 14:30
2211
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...
2023-11-08 13:00
1414
Docquity Expands Digitized Patient Access Programs To Enhance Healthcare Outcomes in Thailand
* After a successful pilot in the Philippines, five DocquityCare Patient Access Programs (PAPs)have been launched in Thailand * DocquityCare PAP will support more than 100 hospitals and 250 healthcare professionals (HCPs) to improve patient care for those with cancer and other life-threatenin...
2023-11-08 10:00
1691
Simulare Medical Launches the Alveolar Bone Graft Simulator
ABG Simulator New Addition to Further Support Cleft Reconstructive Surgical Training TAIPEI, Nov. 8, 2023 /PRNewswire/ -- Simulare Medical, a division of Smile Train Inc. (New York) announces the launch of the Alveolar Bone Graft (ABG) simulator, the latest high-fidelity surgical item in its gro...
2023-11-08 10:00
1758
SP Manufacturing expands into the United States
New Design and Development Center in California provides advanced engineering and development services for SP Manufacturing's global customers. SAN DIEGO, Calif., Nov. 8, 2023 /PRNewswire/ -- SP Manufacturing, a leader in electronic manufacturing services for mission-critical industries, announc...
2023-11-08 10:00
1525
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...
2023-11-08 08:30
1289
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...
2023-11-08 08:30
1585
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...
2023-11-08 02:01
1467
Discovery Life Sciences Announces New CEO
Greg Herrema to Spearhead Next Phase of Global Biospecimen and Biomarker Company's Expansion HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment ofGreg Herrema as its new chief executive officer. A lea...
2023-11-07 23:01
1645
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...
2023-11-07 21:58
1044
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs
* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...
2023-11-07 21:30
2264
Kexing Biopharm Attended CPHI Worldwide 2023
SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...
2023-11-07 20:09
1206
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...
2023-11-07 20:00
1699
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6529
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4461
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4055
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
3501
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
3410